{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:51:27Z","timestamp":1777657887437,"version":"3.51.4"},"reference-count":79,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Psoriasis is a chronic multisystem inflammatory disease associated with a plethora of comorbidities including metabolic syndrome, cardiovascular disease, hypertension, diabetes, hyperlipidemia, obesity, anxiety, depression, chronic kidney disease, and malignancy. Advancement in unveiling new key elements in the pathophysiology of psoriasis led to significant progress in the development of biologic agents which target different signaling pathways and cytokines involved in the inflammatory cascade responsible for the clinical manifestations found in psoriasis. Currently available novel therapeutic options for moderate-severe psoriasis include tumor necrosis factor alpha inhibitors, inhibitors of the interleukin 17, and inhibitors of the interleukin 23. Nevertheless, concerns have been raised with respect to the possible risks associated with the use of biologic therapy requiring close collaboration between dermatologists and physicians of different specialties. Our aim was to perform an in-depth literature review and discuss the potential risks associated with biologic therapy in patients with psoriasis and concurrent diseases with a focus on the influence of novel therapeutic agents on liver function in the context of hepatopathies, particularly viral hepatitis. A multidisciplinary teamwork and periodic evaluation of psoriasis patients under biologic therapy is highly encouraged to obtain an accurate management for each case.<\/jats:p>","DOI":"10.3390\/biology11060808","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T05:12:27Z","timestamp":1653455547000},"page":"808","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4214-4446","authenticated-orcid":false,"given":"Ana","family":"Ion","sequence":"first","affiliation":[{"name":"Department of Dermatology, \u2018Elias\u2019 Emergency University Hospital, 011461 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-7930","authenticated-orcid":false,"given":"Alexandra Maria","family":"Doroban\u021bu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Elias\u2019 Emergency University Hospital, 011461 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana Gabriela","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Elias\u2019 Emergency University Hospital, 011461 Bucharest, Romania"},{"name":"\u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-0088","authenticated-orcid":false,"given":"Mara M\u0103d\u0103lina","family":"Mihai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Elias\u2019 Emergency University Hospital, 011461 Bucharest, Romania"},{"name":"\u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olgu\u021ba Anca","family":"Orzan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Elias\u2019 Emergency University Hospital, 011461 Bucharest, Romania"},{"name":"\u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_2","first-page":"97","article-title":"Current Developments in the Immunology of Psoriasis","volume":"93","author":"Kerstan","year":"2020","journal-title":"Yale J. Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_4","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can Fam Physician"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tokuyama, M., and Mabuchi, T. (2020). New Treatment Addressing the Pathogenesis of Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207488"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","article-title":"Highly Effective New Treatments for Psoriasis Target the IL-23\/Type 17 T Cell Autoimmune Axis","volume":"68","author":"Kim","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","first-page":"S2","article-title":"Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine","volume":"33","author":"Alwan","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jid.2017.04.009","article-title":"Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis","volume":"137","author":"Yiu","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/DDDT.S200147","article-title":"Infliximab and biosimilar infliximab in psoriasis: Efficacy, loss of efficacy, and adverse events","volume":"13","author":"Subedi","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.12788\/j.sder.0070","article-title":"Tumor necrosis factor inhibitors in psoriasis: An update","volume":"33","author":"Kerdel","year":"2014","journal-title":"Semin. Cutan Med. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjd.13004","article-title":"Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice","volume":"171","author":"Shear","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1346-8138.2010.00971.x","article-title":"Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma","volume":"38","author":"Torii","year":"2011","journal-title":"J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jaad.2010.03.009","article-title":"Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study","volume":"64","author":"Strober","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"ref_27","unstructured":"(2022, April 06). Siliq (Brodalumab) Injection, for Subcutaneous Use. US FDA Approved Product Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Caputo, V., Strafella, C., Cosio, T., Lanna, C., Campione, E., Novelli, G., Giardina, E., and Cascella, R. (2021). Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. Genes, 12.","DOI":"10.3390\/genes12091398"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Membrive Jim\u00e9nez, C., P\u00e9rez Ram\u00edrez, C., S\u00e1nchez Mart\u00edn, A., Vieira Maroun, S., Arias Santiago, S.A., Ram\u00edrez Tortosa, M.D.C., and Jim\u00e9nez Morales, A. (2021). Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11040293"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Jin, Y., Lee, H., Lee, M.P., Landon, J.E., Merola, J.F., Desai, R.J., and Kim, S.C. (2021). Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis. Arthritis Care Res.","DOI":"10.1002\/acr.24630"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjd.17036","article-title":"Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"180","author":"Yiu","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jdv.16866","article-title":"Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis\u2014Time for a paradigm change","volume":"35","author":"Nogueira","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjd.19158","article-title":"The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: The Northern Italy experience","volume":"183","author":"Gisondi","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_48","first-page":"1","article-title":"Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management","volume":"12","author":"Yiu","year":"2022","journal-title":"Psoriasis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16715","article-title":"Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: A meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland","volume":"179","author":"Descalzo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0019-5359.16655","article-title":"Current status of TNF blocking therapy in heart failure","volume":"59","author":"Gupta","year":"2005","journal-title":"Indian J. Med. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/jdv.16018","article-title":"Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: A prospective cohort study","volume":"34","author":"Rungapiromnan","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders","volume":"10","author":"Garcovich","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjd.20527","article-title":"Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab","volume":"185","author":"Brunner","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: Unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn\u2019s Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: Risk of new onset IBD with the use of anti-interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: Role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_60","first-page":"1","article-title":"Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics","volume":"33","author":"Ataseven","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s10067-012-2072-7","article-title":"Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept","volume":"31","author":"Blom","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2340\/00015555-2644","article-title":"Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab","volume":"97","author":"Hoffmann","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/09546634.2018.1430301","article-title":"Safety of biologic agents for psoriasis in patients with viral hepatitis","volume":"29","author":"AlMutairi","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_66","first-page":"477","article-title":"Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database","volume":"106","author":"Vanaclocha","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3s","DOI":"10.1177\/1203475418811347","article-title":"Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update","volume":"23","author":"Poelman","year":"2019","journal-title":"J. Cutan Med. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaad.2019.12.001","article-title":"Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: A 9-year multicenter cohort study","volume":"85","author":"Chiu","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/bjd.17444","article-title":"Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and\/or C","volume":"180","author":"Siegel","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab","volume":"38","author":"Ting","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/jdv.15177","article-title":"Position statement for the management of comorbidities in psoriasis","volume":"32","author":"Dauden","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s10067-020-05391-y","article-title":"Clinicians\u2019 perspectives of shared care of psoriatic arthritis and psoriasis between rheumatology and dermatology: An interview study","volume":"40","author":"Sumpton","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/120347541201600305","article-title":"Biologic therapy in psoriasis: Perspectives on associated risks and patient management","volume":"16","author":"Papp","year":"2012","journal-title":"J. Cutan Med. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5114\/ada.2020.96155","article-title":"Management of psoriatic patients in biologic treatment associated with infectious comorbidities","volume":"37","author":"Nicoletta","year":"2020","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"314","DOI":"10.17235\/reed.2019.6263\/2019","article-title":"Psoriasis and fatty liver: A harmful synergy","volume":"111","author":"Olveira","year":"2019","journal-title":"Rev. Esp. Enferm. Dig."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/11\/6\/808\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:10Z","timestamp":1760138290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/11\/6\/808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":79,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["biology11060808"],"URL":"https:\/\/doi.org\/10.3390\/biology11060808","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}